title: [Programs for continuing medical education: a session; 2. Current therapy for chronic hepatitis C].
authors.forename: Michio
authors.initials: M
authors.lastname: Imamura
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Chayama
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000235:genetics; D004359:Drug Therapy, Combination; D004502:Education, Medical, Continuing; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D007372:Interferons; D007378:Interleukins / Q000235:genetics; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control; D009842:Oligopeptides / Q000008:administration & dosage*; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011480:Protease Inhibitors / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage*; D000069616:Simeprevir; D013449:Sulfonamides / Q000008:administration & dosage*; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D006575:Heterocyclic Compounds, 3-Ring; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D009842:Oligopeptides; D011092:Polyethylene Glycols; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D012254:Ribavirin; D000069616:Simeprevir; D013449:Sulfonamides; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C486464:telaprevir; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a